Harbin Yuhuang Pharmaceutical

Harbin Yuhuang Pharmaceutical, commonly known as Gloria Pharmaceuticals, is a prominent Chinese pharmaceutical company engaged in the research, development, manufacturing, and sale of a wide range of medical products. The company's portfolio spans multiple therapeutic areas, including oncology, cardiovascular diseases, orthopedics, and anti-infectives. Gloria Pharmaceuticals is notably active in the development of innovative biologics, such as its PD-1 inhibitor zimberelimab, which has received regulatory approval in China. The company operates several manufacturing bases and maintains a significant commercial presence across the Chinese domestic market. Through strategic partnerships and internal R&D, it continues to expand its pipeline into advanced therapeutic modalities.